2023
Pneumococcal Infections in Children with Sickle Cell Disease Before and After Pneumococcal Conjugate Vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal Infections in Children with Sickle Cell Disease Before and After Pneumococcal Conjugate Vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American children
2021
Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study. The Lancet Regional Health - Europe 2021, 7: 100126. PMID: 34557837, PMCID: PMC8454757, DOI: 10.1016/j.lanepe.2021.100126.Peer-Reviewed Original ResearchInvasive pneumococcal diseasePneumococcal vaccine uptakeVaccine effectivenessPneumococcal vaccinationPneumococcal diseaseVaccine uptakeOlder adultsSerotype 3 invasive pneumococcal diseaseSerotype 3Indirect cohort methodOverall vaccine effectivenessRetrospective cohort studyInvestigator-initiated research grantIPD episodesCohort studyPneumococcal vaccinePolysaccharide vaccineVaccination statusPPV23Age groupsCohort methodVaccinationAdultsSerotypesVaccine
2019
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
van der Linden M, Imöhl M, Perniciaro S. Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLOS ONE 2019, 14: e0220453. PMID: 31369597, PMCID: PMC6675109, DOI: 10.1371/journal.pone.0220453.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSerotype 3 invasive pneumococcal diseaseHerd protection effectsIPD casesAge groupsPCV13-type invasive pneumococcal diseaseAdult invasive pneumococcal diseaseAdult pneumococcal vaccinationPneumococcal vaccination programAdults 60 yearsVaccine serotypes 4Years of ageAdult age groupsIndirect protection effectPneumococcal vaccinationPneumococcal diseasePolysaccharide vaccineVaccine recommendationsChildhood vaccinationVaccination programVaccine formulationsAdult coverageAdults 60Protection effectSerotype 4Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study
Arifin SMN, Zimmer C, Trotter C, Colombini A, Sidikou F, LaForce FM, Cohen T, Yaesoubi R. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study. Medical Decision Making 2019, 39: 553-567. PMID: 31268405, PMCID: PMC6786941, DOI: 10.1177/0272989x19859899.Peer-Reviewed Original ResearchConceptsReactive campaignsSerogroup replacementConjugate vaccineOne-time catchPolyvalent meningococcal vaccineRoutine infant vaccinationMeningococcal conjugate vaccineMeningococcal polysaccharide vaccineRoutine infant immunizationCurrent vaccination practicesImportant health benefitsCost-effectiveness thresholdStandard cost-effectiveness thresholdsAgent-based transmission modelVaccination seriesImmunization seriesInfant vaccinationInfant immunizationPolysaccharide vaccineMeningococcal vaccineVaccination practicesPolyvalent vaccineLaboratory confirmationMenAfriVacSerogroups A
2016
Pneumococcal Vaccination Strategies. An Update and Perspective
Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal Vaccination Strategies. An Update and Perspective. Annals Of The American Thoracic Society 2016, 13: 933-944. PMID: 27088424, PMCID: PMC5461988, DOI: 10.1513/annalsats.201511-778fr.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInvasive pneumococcal diseasePneumococcal diseasePneumococcal vaccineNext-generation pneumococcal vaccinesPneumococcal vaccine recommendationsVaccination of infantsPneumococcal polysaccharide vaccineNasal carriage ratePneumococcal conjugate vaccineChronic pulmonary diseaseProtein-conjugate vaccineImplementation of vaccinesMucosal immunity responseBasis of agePneumococcal vaccinationImportant global pathogenPneumococcal pneumoniaPneumococcal infectionPolysaccharide vaccineVaccine recommendationsCommon presentationConjugate vaccinePulmonary diseaseVaccine indicationsCarriage rate
2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)
Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.Peer-Reviewed Original ResearchConceptsAutoimmune lymphoproliferative syndromeAutoimmune hemolytic anemiaRefractory immune thrombocytopeniaMedian response durationUse of rituximabDisorder of apoptosisMarked lymphadenopathyProlonged neutropeniaRituximab infusionRituximab useSurgical splenectomyALPS patientsImmune thrombocytopeniaPalpable spleenRituximab therapySignificant splenomegalyPolysaccharide vaccineAutoimmune destructionMedication optionsMultilineage cytopeniasRefractory cytopeniaAutoreactive lymphocytesAsplenic individualsAntibody responseLymphoproliferative syndrome
2008
Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study
Rodriguez-Barradas MC, Goulet J, Brown S, Goetz MB, Rimland D, Simberkoff MS, Crothers K, Justice AC. Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study. Clinical Infectious Diseases 2008, 46: 1093-1100. PMID: 18444830, PMCID: PMC3115628, DOI: 10.1086/529201.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccineVeterans Aging CohortPPV vaccinationIncidence of pneumoniaAging CohortCox proportional hazards regression methodsLow CD4 cell countsProportional hazards regression methodsCD4 cell countHIV infection statusRisk of pneumoniaLower hemoglobin levelsBenefits of vaccinationHuman immunodeficiency virusOngoing prospective studyElectronic medical recordsPneumococcal vaccinationPneumonia eventsUnvaccinated patientsCurrent smokingPneumococcal diseasePolysaccharide vaccineVaccination statusHIV infectionRetrospective review
2007
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).
Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.Peer-Reviewed Original ResearchAutoimmune lymphoproliferative syndromeALPS patientsMycophenolate mofetilRituximab therapyDouble-negative T lymphocytesALPS phenotypeNegative T lymphocytesUse of rituximabCompletion of therapyRed cell transfusionAdult male patientsNIH Clinical CenterLong-term riskDurable normalizationPneumococcal sepsisPrednisone pulsesRefractory ITPRituximab infusionRituximab useWeekly vincristineCell transfusionHepatitis CImmune thrombocytopeniaPalpable spleenPolysaccharide vaccine
2005
Delivering Pneumococcal Vaccine to a High Risk Population: The Navajo Experience
Benin AL, Watt JP, O'Brien KL, Reid R, Zell ER, Katz S, Donaldson C, Schuchat A, Santosham M, Whitney CG. Delivering Pneumococcal Vaccine to a High Risk Population: The Navajo Experience. Human Vaccines & Immunotherapeutics 2005, 1: 66-69. PMID: 17038821, DOI: 10.4161/hv.1.2.1562.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedArizonaCross-Sectional StudiesDelivery of Health CareFemaleHumansImmunization ProgramsIndians, North AmericanMaleMiddle AgedNew MexicoPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillanceRiskSample SizeUnited StatesUnited States Public Health ServiceUtahConceptsIndian Health ServiceVaccine indicationsVaccination programHealth servicesPneumococcal polysaccharide vaccineHealthy People 2010High-risk populationPublic health nursingCross-sectional studyNavajo adultsPneumococcal diseasePneumococcal vaccinePolysaccharide vaccineMedical chartsPreventable diseaseHealth nursingPersons 18Home visitsRisk populationsUniversal health insuranceExcellent delivery systemHealth insuranceNavajo patientsVaccineHigh rateValidation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the sickness prevention achieved through regional collaboration (SPARC) program
Shenson D, DiMartino D, Bolen J, Campbell M, Lu P, Singleton J. Validation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the sickness prevention achieved through regional collaboration (SPARC) program. Vaccine 2005, 23: 1015-1020. PMID: 15620474, DOI: 10.1016/j.vaccine.2004.07.039.Peer-Reviewed Original ResearchConceptsBehavioral Risk Factor Surveillance SystemPneumococcal vaccination statusPneumococcal vaccinationVaccination statusBRFSS surveyBehavioral Risk Factor Surveillance SurveySelf-reported pneumococcal vaccinationRisk Factor Surveillance SurveyRisk Factor Surveillance SystemPneumococcal polysaccharide vaccineLocal health care agencyPopulation-based surveyPrimary surveillance toolSickness preventionHealth care agenciesPneumococcal immunizationPolysaccharide vaccineMedical recordsMedicare claimsSurveillance SurveyFour-county areaSubset of respondentsCare agenciesSurveillance toolVaccination
2004
Invasive Pneumococcal Disease among Navajo Adults, 1989–1998
Watt J, O'Brien K, Benin A, Whitney C, Robinson K, Parkinson A, Reid R, Santosham M. Invasive Pneumococcal Disease among Navajo Adults, 1989–1998. Clinical Infectious Diseases 2004, 38: 496-501. PMID: 14765341, DOI: 10.1086/381198.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseNavajo adultsPneumococcal diseaseEpidemiology of IPDRates of IPDPneumococcal polysaccharide vaccineCase fatality rateGeneral US populationPercent of casesBlack personsPolysaccharide vaccineAnnual incidenceActive surveillanceMedical recordsElevated riskPrevention strategiesUS populationDiseaseCorresponding ratesAdditional researchAdultsUnited StatesRiskPatientsVaccine
2003
Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults
Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG. Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults. The Journal Of Infectious Diseases 2003, 188: 81-89. PMID: 12825175, DOI: 10.1086/375782.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseOverall vaccine effectivenessNavajo adultsPneumococcal diseaseCase patientsControl patientsPolysaccharide vaccineVaccine effectivenessGeneral United States populationSerious pneumococcal diseasePneumococcal polysaccharide vaccineCohort methodologyUnited States populationCase-control setsActive surveillanceObservational studyMedical conditionsPatientsMedical careDiseaseAdultsDiabetesRegression analysisVaccineAlcoholism
1999
Pneumococcal vaccines: history, current status, and future directions
Butler J, Shapiro E, Carlone G. Pneumococcal vaccines: history, current status, and future directions. The American Journal Of Medicine 1999, 107: 69-76. PMID: 10451012, DOI: 10.1016/s0002-9343(99)00105-9.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccinePolysaccharide vaccinePneumococcal infectionCertain underlying medical conditionsSerious pneumococcal diseaseCommunity-acquired pneumoniaPneumococcal conjugate vaccineUnderlying medical conditionsAnti-pneumococcal antibodiesLarger efficacy trialPrevention of infectionDrug-resistant strainsImmunocompetent childrenPneumococcal diseasePneumococcal vaccineBacterial meningitisConjugate vaccineCase fatalityDNA vaccineInvasive infectionsPneumococcal polysaccharideEfficacy trialsImmune responseMedical conditionsHigh risk
1991
Antibody Responses to Haemophilus influenzae Type b Vaccines in Men with Human Immunodeficiency Virus Infection
Steinhoff M, Auerbach B, Nelson K, Vlahov D, Becker R, Graham N, Schwartz D, Lucas A, Chaisson R. Antibody Responses to Haemophilus influenzae Type b Vaccines in Men with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1991, 325: 1837-1842. PMID: 1683682, DOI: 10.1056/nejm199112263252603.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionInfluenzae type b vaccineAsymptomatic HIV infectionImmunodeficiency virus infectionSymptomatic HIV infectionType b vaccineHIV infectionAntibody responsePRP vaccineB vaccineVirus infectionH. influenzae type b vaccineHaemophilus influenzae type b vaccineType b polysaccharide vaccineGeometric mean antibody titersHIV-seropositive menPRP antibody titersPutative protective levelGreater antibody responseH. influenzae type b.Mean antibody titersSeronegative subjectsCD4 lymphocytesPolysaccharide vaccineSeronegative menThe Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine
Shapiro E, Berg A, Austrian R, Schroeder D, Parcells V, Margolis A, Adair R, Clemens J. The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide Vaccine. New England Journal Of Medicine 1991, 325: 1453-1460. PMID: 1944423, DOI: 10.1056/nejm199111213252101.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal infectionsPneumococcal polysaccharide vaccinePneumococcal vaccineProtective efficacyPneumococcal infectionCase patientsImmunocompetent patientsPolysaccharide vaccineVaccination historyHospital-based case-control studyPolyvalent pneumococcal polysaccharide vaccineSerious pneumococcal infectionsSite of hospitalizationVaccine protective efficacyPolyvalent pneumococcal vaccineCase-control studyProspective surveillanceRandomized trialsSterile sitesPatientsS. pneumoniaeMedical careStreptococcus pneumoniaeVaccineInfection
1990
Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine.
Shapiro E, Berg A. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. 1990, 85: 643-7. PMID: 2179854, DOI: 10.1542/peds.85.4.643.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType b polysaccharide vaccineH influenzae type b polysaccharide vaccineHaemophilus influenzae type b polysaccharide vaccinePolysaccharide vaccineProtective efficacyMonths of ageVaccine failureInvasive diseaseH influenzae type b.Immunization Practices Advisory CommitteeH influenzae type bVaccine protective efficacyRandomized clinical trialsInfluenzae type bAvailable epidemiologic dataNormal serum concentrationsYears of ageTotal immunoglobulinSerum concentrationsImmune deficiencyClinical trialsEpidemiologic dataHemolytic complementVaccineChildren 18
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply